Corcept Therapeutics reported a 35% reduction in risk of death when its selective glucocorticoid receptor antagonist relacorilant was added to chemotherapy in platinum‑resistant ovarian cancer, data that followed progression‑free survival gains and bolstered the company ahead of a July 11, 2026 PDUFA. The phase 3 Rosella trial results prompted a large share move and revived momentum after a prior FDA complete response letter for a different indication. Analysts project relacorilant could reach a multi‑billion dollar market if approved and expanded beyond platinum‑resistant disease.